Routine prescription of a hematopoietic growth factor, lenograstime: Results and critical analysis of a national survey 1995-1996;Prescription d'un facteur de croissance hematopoietique, le lenograstime, en pratique courante: Resultats et commentaires, a partir d'une enquete nationale realisee d'avril 1995 a mars 1996

Presse Medicale

Volumn 27, Issue 24, 1998, Pages 1203-1212

  Maurice Tison, S ^a   Schuller, M P ^b   Salamon, R ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; FOLLOW UP; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; PRESCRIPTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITAL RECORDS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; NEOPLASMS; PRESCRIPTIONS, DRUG; RECOMBINANT PROTEINS;

EID: 0032508271     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. American Society of Clinical Oncology. Recommendations for the use of haematopoietic colony stimulating factors : evidence based, clinical practice guidelines. J Clin Oncol 1994 ; 12:2471-508.
2. Update of recommendations for the use of haematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1996 ; 14:1957-60.
3. Blay JY, Fervers B, Latour JF, Philip T. Standards, options et recommandations pour l'utilisation des facteurs de croissance hématopoïétique en cancérologie. Bull Cancer 1995 ; 82(suppl 4):S487-508.
4. Hill C, Doyon F, Sancho-Garnier H. Epidémiologie des cancers, Flammarion Médecine-Science, Paris, 1997.